Predicting hormone therapy resistance in metastatic breast cancer
Part of Cancer, Skin clinical trials.
This study tests whether a special PET scan and a blood test can help predict how well hormone therapy will work for people with metastatic breast cancer. The goal is to find better ways to personalize treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have breast cancer that is ER-positive and HER2-negative (a type that uses hormones to grow).
- You are about to start your first treatment for metastatic breast cancer with an aromatase inhibitor plus a CDK4/6 inhibitor within the next 60 days.
- You will have a PET scan before starting treatment.
- Your cancer has measurable or visible spread to other parts of the body.
- You are able to care for yourself (ECOG performance status 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET scan (FDG PET-CT) can better track how well treatment is working for people with advanced breast cancer. It may help doctors choose the best therapy and monitor response over time.
This trial is testing a special PET scan (18F-FES PET/CT) to see if it can find distant cancer spread in women with a slow-growing, estrogen receptor-positive, stage III breast cancer. The goal is to find out whether this imaging test can detect hidden metastases better than standard scans.
This trial tests a new imaging technique (18F-FES PET/CT) along with blood markers to guide treatment for metastatic breast cancer that is ER-positive and HER2-negative. It's for people whose cancer progressed on first-line hormone therapy and who are starting a second line of hormone therapy.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
Hear when a new Metastatic Breast Cancer (HR+/ HER2-) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.